Breaking News Instant updates and real-time market news.

GLPG

Galapagos

$195.84

2.9 (1.50%)

06:30
12/02/19
12/02
06:30
12/02/19
06:30

Galapagos initiated with a Neutral at BofA/Merrill

BofA/Merrill analyst Jason Gerberry initiated coverage of Galapagos with a Neutral rating and $199 price target. The analyst is positive on the company's lead filgotinib asset targeting rheumatoid arthritis and expects the drug to gain FDA approval next year, but he also sees "limited catalysts" over the near term.

  • 02

    Dec

  • 21

    Feb

GLPG Galapagos
$195.84

2.9 (1.50%)

09/09/19
MSCO
09/09/19
INITIATION
Target $200
MSCO
Overweight
Galapagos resumed with an Overweight at Morgan Stanley
Morgan Stanley analyst Matthew Harrison resumed coverage of Galapagos with an Overweight rating and $200 price target.
09/10/19
MSCO
09/10/19
INITIATION
Target $200
MSCO
Overweight
Galapagos resumed with an Overweight at Morgan Stanley
Morgan Stanley analyst Matthew Harrison resumed coverage of Galapagos (GLPG) with an Overweight rating and $200 price target. The analyst believes Galapagos is well positioned for success following the transaction with Gilead (GILD). He believes Gilead offers a "strong partner" to drive the company's "broad" pipeline while building commercial operations in Europe. Filgotinib will drive near-term upside in Galapagos shares while its greater than $5B cash position provides downside protection, Harrison tells investors in a research note.
10/29/19
CANT
10/29/19
NO CHANGE
Target $187
CANT
Overweight
Galapagos outlook unchanged after MOR106 discontinuation, says Cantor Fitzgerald
Cantor Fitzgerald analyst Eliana Merle says she still expects a "strong" 2020 from Galapagos following the announcement that clinical development of MOR106 in atopic dermatitis has been stopped for futility. The analyst lowered her price target for the shares to $187 from $188 and reiterates an Overweight rating on the name. She thinks there was "limited investor credit baked in" for the MOR106 program and that Galapagos had relatively limited economics. Many clinical catalysts in 2020 are underappreciated for Galapagos, Merle tells investors in a research note.
11/15/19
RBCM
11/15/19
NO CHANGE
Target $158
RBCM
Sector Perform
Galapagos price target raised to $158 from $152 at RBC Capital
RBC Capital analyst Brian Abrahams raised his price target on Galapagos (GLPG) to $158 after the company's R&D day, where the management revealed its "expansive plans for bringing new discovery techniques, treatment modalities, preclinical assets, and targeted indications online" by using the cash from its recent Gilead (GILD) deal. While these "aspirations" will take time to mature, the analyst says the plans are "impressive". Abrahams still keeps his Sector Perform rating on Galapagos shares, noting that its nearer term positives of filgotinib commercialization in RA and potential expansion into IB look priced in.

TODAY'S FREE FLY STORIES

SPT

Sprout Social

20:34
12/12/19
12/12
20:34
12/12/19
20:34
Syndicate
Sprout Social 8.824M share IPO priced at $17.00 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 13

    Dec

SCHW

Charles Schwab

$51.08

1.48 (2.98%)

20:16
12/12/19
12/12
20:16
12/12/19
20:16
Upgrade
Charles Schwab rating change at Keefe Bruyette »

Charles Schwab upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLUE

Bluebird Bio

$84.00

-2.97 (-3.41%)

20:08
12/12/19
12/12
20:08
12/12/19
20:08
Upgrade
Bluebird Bio rating change at Oppenheimer »

Bluebird Bio upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AQST

Aquestive Therapeutics

$6.73

-0.97 (-12.60%)

20:07
12/12/19
12/12
20:07
12/12/19
20:07
Syndicate
Aquestive Therapeutics 7M share Secondary priced at $5.00 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

BY

Byline Bancorp

$18.95

0.54 (2.93%)

19:56
12/12/19
12/12
19:56
12/12/19
19:56
Hot Stocks
Byline Bancorp initiates 3c per share cash dividend »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 18

    Dec

NXGN

NextGen Healthcare

$16.83

-1.28 (-7.07%)

19:08
12/12/19
12/12
19:08
12/12/19
19:08
Downgrade
NextGen Healthcare rating change at Cantor Fitzgerald »

NextGen Healthcare…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

AMOT

Allied Motion

$46.79

0.81 (1.76%)

18:57
12/12/19
12/12
18:57
12/12/19
18:57
Hot Stocks
Allied Motion CEO sells 10K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LILA

Liberty Latin America

$17.56

0.32 (1.86%)

, DISCA

Discovery

$32.36

0.28 (0.87%)

18:54
12/12/19
12/12
18:54
12/12/19
18:54
Hot Stocks
Liberty Latin America says Dr. John Malone retires from board »

Liberty Latin America…

LILA

Liberty Latin America

$17.56

0.32 (1.86%)

DISCA

Discovery

$32.36

0.28 (0.87%)

LGF.A

Lionsgate

$9.99

0.65 (6.96%)

LGF.B

Lionsgate

$9.35

0.7 (8.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOCPY

Hoya Corp.

$0.00

(0.00%)

, TOSBF

Toshiba, also use TOSYY

$0.00

(0.00%)

18:43
12/12/19
12/12
18:43
12/12/19
18:43
Hot Stocks
Hoya to offer JPY12,900 per share in tender offer for Toshiba unit NuFlare »

Hoya Corporation (HOCPY)…

HOCPY

Hoya Corp.

$0.00

(0.00%)

TOSBF

Toshiba, also use TOSYY

$0.00

(0.00%)

TOSYY

Toshiba

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

ADBE

Adobe

$305.76

2.01 (0.66%)

, SRPT

Sarepta

$100.39

-1.15 (-1.13%)

18:42
12/12/19
12/12
18:42
12/12/19
18:42
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Adobe…

ADBE

Adobe

$305.76

2.01 (0.66%)

SRPT

Sarepta

$100.39

-1.15 (-1.13%)

DDOG

Datadog

$35.75

0.23 (0.65%)

RIG

Transocean

$5.94

0.28 (4.95%)

TPR

Tapestry

$26.35

0.515 (1.99%)

GTIM

Good Times Restaurants

$1.71

0.14 (8.92%)

ORCL

Oracle

$56.47

0.16 (0.28%)

AVGO

Broadcom

$327.39

7.53 (2.35%)

COST

Costco

$297.50

2.28 (0.77%)

CNC

Centene

$58.52

-0.13 (-0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

  • 13

    Dec

  • 23

    Jan

  • 23

    Mar

SRPT

Sarepta

$100.39

-1.15 (-1.13%)

18:40
12/12/19
12/12
18:40
12/12/19
18:40
Hot Stocks
Breaking Hot Stocks news story on Sarepta »

Sarepta up 28.5% after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PHR

Phreesia

$28.67

0.1 (0.35%)

18:38
12/12/19
12/12
18:38
12/12/19
18:38
Syndicate
Phreesia 6.75M share Secondary priced at $26.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

SRPT

Sarepta

$100.39

-1.15 (-1.13%)

18:31
12/12/19
12/12
18:31
12/12/19
18:31
Hot Stocks
Breaking Hot Stocks news story on Sarepta »

Sarepta to resume trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$305.76

2.01 (0.66%)

18:25
12/12/19
12/12
18:25
12/12/19
18:25
Hot Stocks
Adobe CEO: We are not overly concerned with the trade war with China »

Comment from interview…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 23

    Jan

SRPT

Sarepta

$100.39

-1.15 (-1.13%)

18:20
12/12/19
12/12
18:20
12/12/19
18:20
Hot Stocks
Sarepta announces FDA approval of VYONDYS 53 injection to treat DMD »

Sarepta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,760.44

11.33 (0.65%)

18:11
12/12/19
12/12
18:11
12/12/19
18:11
Hot Stocks
Amazon orders fourth season of 'The Marvelous Mrs. Maisel' »

Amazon Studios announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OHAI

OHA Investment

$1.28

(0.00%)

, PTMN

Portman Ridge Finance

$2.04

(0.00%)

18:10
12/12/19
12/12
18:10
12/12/19
18:10
Hot Stocks
OHA Investment obtains stockholder approval of Portman Ridge deal »

OHA Investment…

OHAI

OHA Investment

$1.28

(0.00%)

PTMN

Portman Ridge Finance

$2.04

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONCT

Oncternal Therapeutics

$4.62

0.05 (1.09%)

18:05
12/12/19
12/12
18:05
12/12/19
18:05
Hot Stocks
Oncternal presents interim data from Phase 1b clinical study of cirmtuzumab »

Oncternal Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HZN

Horizon Global

$3.49

0.14 (4.18%)

18:03
12/12/19
12/12
18:03
12/12/19
18:03
Hot Stocks
Horizon Global CFO Jamie Pierson steps down »

Horizon Global announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$56.47

0.16 (0.28%)

18:03
12/12/19
12/12
18:03
12/12/19
18:03
Hot Stocks
Oracle CEO Catz says expects momentum in 2H20 to carry into FY21 »

Says feels "very…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

SRPT

Sarepta

$100.39

-1.15 (-1.13%)

18:00
12/12/19
12/12
18:00
12/12/19
18:00
Hot Stocks
Breaking Hot Stocks news story on Sarepta »

Sarepta trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$56.47

0.16 (0.28%)

17:52
12/12/19
12/12
17:52
12/12/19
17:52
Hot Stocks
Oracle's Ellison says 'we have no plans for having a second CEO' »

Says there won't be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

NLNK

NewLink Genetics

$1.61

-0.015 (-0.93%)

, EVRC

Evercel, Inc

$0.00

(0.00%)

17:41
12/12/19
12/12
17:41
12/12/19
17:41
Hot Stocks
NewLink Genetics advances over 11% after Evercel discloses rejected offer »

Shares of NewLink…

NLNK

NewLink Genetics

$1.61

-0.015 (-0.93%)

EVRC

Evercel, Inc

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVRC

Evercel, Inc

$0.00

(0.00%)

, NLNK

NewLink Genetics

$1.61

-0.015 (-0.93%)

17:36
12/12/19
12/12
17:36
12/12/19
17:36
Hot Stocks
Evercel announces rejected offer to acquire NewLink Genetics »

Evercel (EVRC) has made…

EVRC

Evercel, Inc

$0.00

(0.00%)

NLNK

NewLink Genetics

$1.61

-0.015 (-0.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BXRX

Baudax Bio

$6.30

0.225 (3.70%)

17:34
12/12/19
12/12
17:34
12/12/19
17:34
Hot Stocks
Corsair Capital reports 8.77% passive stake in Baudax Bio »

Corsair Capital disclosed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.